CervoMed nfvPPA trial data to be presented at ISFTD meeting

September 10, 2026 7:30 AM

CervoMed Inc. (NASDAQ: CRVO) announced that initial biomarker results from its Phase 2a clinical trial of neflamapimod in nonfluent variant ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found